Actinic Keratosis Olsen Grade I/II
Conditions
Brief summary
In this three-armed dose-finding trial 3 AK 3012 topical formulations shall be investigated with respect to safety and efficacy in order to identify the optimal concentration in the topical formulation. The main objective of the trial is to determine the optimal concentration of the active agent in the topical formulation as quantified by the change of the number of skin alterations in pre-defined areas in a time period from inclusion in the trial until the end of treatment (3 months) or prior complete healing.
Interventions
DRUGAK 3012
cutaneous use twice a day
Sponsors
CenTrial GmbH
d.s.h. statistical services GmbH
Dolorgiet GmbH & Co. KG
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age: ≥ 18 years * Gender: male and female * Actinic Keratosis (Olsen grade I/II) * at least 5 actinic keratoses on the scalp, forehead, face, extremities, and/ or decollete * no treatment of the actinic keratoses within the previous 3 months before inclusion in the study * histologic confirmation of the diagnosis actinic keratosis by biopsy * good general condition * normal laboratory values (creatinine, urea, Glutamate-Oxalacetate Transaminase (GOT),Glutamate-Pyruvate Transaminase (GPT), gamma-glutamyl transferase (GGT), Lactate dehydrogenase (LDH)) and blood count at study start not higher than 1.5 x upper norm limit * Female patients must be tested negative for pregnancy before inclusion in the trial. During the trial, female patients have to apply a generally accepted form of birth control (i.e. oral estrogen- and gestagen containing contraceptives; estrogen containing skin plaster/ tape, hormone implant, hormone contraceptive coil, sterilisation; sexual abstinence) or being post-menopausal for at least 2 years. * Willing and able to participate in the screening and all trial specific procedures in compliance with the protocol * Signed written informed consent
Exclusion criteria
* Known allergy against nonsteroidal antiphlogistics and/ or against excipients of the investigational medicinal product * Presence of immunosuppression * Treatment with 5-fluorouracil, cyclosporine, retinoids, glycolic acid, imiquimod, trichloroacetic acid during the trial or 12 weeks before inclusion in the trial * Continuous treatment with nonsteroidal antiphlogistics with the exception of low-dose acetylsalicylic acid (100 mg) for inhibition of thrombocyte aggregation * Planned treatment with photodynamic therapy during participation in the trial * Pregnancy or lactation * Participation in another clinical trial within 3 months before inclusion in the current trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of skin alterations during treatment period | 90 days: Between Visit 0 (day 0) and Visit 3 (day 90) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of visible skin alterations during treatment period | 90 days: Between Visit 0 (day 0) and Visit 3 (day 90) | — |
| Tolerability of the investigated medicinal product | 90 days: Between Visit 0 (day 0) and Visit 3 (day 90) | Tolerability will be assessed on the basis of adverse events |
| Adverse events | 90 days: Between Visit 0 (day 0) and Visit 3 (day 90) | — |
Countries
Germany
Outcome results
None listed